Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
The identification of NTG was based on reproducible glaucomatous visual field defects, corresponding to typical ONH changes.~Unilateral or bilateral visual field loss (description as below) as determined by at least two consecutive automated static threshold perimetry tests.~One eye is randomly selected in the cases where both eyes are treated.~Inclusion criteria:~1. age ranging from 45 to 75 years~2. best-corrected visual acuity no worse than 20/30 Snellen equivalent~3. optic nerve head cupping (i.e., a vertical cup-to-disc ratio of more than 0.6) and/or notching of neuroretinal rim, and/or retinal nerve fiber defects characteristic of glaucoma~4. visual field loss (i.e., a localized defect with at least three adjacent nonedge points depressed \>5 dB from the normal value, and a nucleus of at least one point depressed 10 dB from the normal value)~5. repeated measurements of untreated IOP, which documented values less than 22 mmHg~6. central corneal thickness ranging from 540 to 560 microns~7. open-angle confirmed by gonioscopy~Exclusion criteria:~1. active or chronic systemic diseases and/or concomitant assumption of any medication known to affect IOP, BP and/or HR~2. corneal abnormalities preventing reliable applanation tonometry~3. severe ocular trauma, ocular inflammation or infection, intraocular surgery or argon laser treatment or laser trabeculoplasty~4. myopic or other fundus changes preventing reliable optic disc evaluation,~5. visual field defects caused by nonglaucomatous disease~6. history of allergy to the ingredients of Cosopt or Xalatan eye drops

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
- Arm 2 (Type: ACTIVE_COMPARATOR): Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).